About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
SOPHiA GENETICS SA (SOPH): Insider Trades and Fund Holdings
In the past 12 months, SOPHiA GENETICS SA insiders reported no open-market purchases and 30 sales worth $1.62M; 28 of the sales were reported as made under a 10b5-1 trading plan.
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144), Congress trades and fund moves in the past year, newest first.
- Oct 13, 2026Insider saleChief Scientific Officer Zhenyu Xu sold $28,727 under a 10b5-1 plan
- Oct 12, 2026Insider saleExecutive Chair Jurgi Camblong sold $61,671 under a 10b5-1 plan
- Oct 12, 2026Insider saleChief Medical Officer Philippe Menu sold $36,303 under a 10b5-1 plan
- Oct 5, 2026Insider saleExecutive Chair Jurgi Camblong sold $326,526 under a 10b5-1 plan
- Oct 5, 2026Insider saleCEO Ross Muken sold $79,971 under a 10b5-1 plan
- Oct 5, 2026Insider saleChief Medical Officer Philippe Menu sold $60,100 under a 10b5-1 plan
- Oct 5, 2026Insider saleChief Scientific Officer Zhenyu Xu sold $60,075 under a 10b5-1 plan
- Oct 5, 2026Insider saleGeneral Counsel Van Well Daan sold $50,100 under a 10b5-1 plan
- Oct 5, 2026Insider saleCTO Abhimanyu Verma sold $42,929 under a 10b5-1 plan
- Oct 5, 2026Insider saleChief People Officer Manuela Valente sold $34,487 under a 10b5-1 plan
- Oct 5, 2026Insider saleCFO George Cardoza sold $12,897 under a 10b5-1 plan
- Oct 5, 2026Insider saleChief Sales Officer Kevin Puylaert sold $1,737
- Oct 5, 2026Planned saleJURGI CAMBLONG (director, officer) filed notice to sell about $529,973 around Oct 5, 2026
- Oct 5, 2026Planned salePHILIPPE MENU (officer) filed notice to sell about $180,720 around Oct 5, 2026
- Oct 5, 2026Planned saleZHENYU XU (officer) filed notice to sell about $156,510 around Oct 5, 2026
- Oct 5, 2026Planned saleROSS J MUKEN (director, officer) filed notice to sell about $79,393 around Oct 5, 2026
- Oct 5, 2026Planned saleDAAN GUIDO MARIA VAN WELL (officer) filed notice to sell about $49,776 around Oct 5, 2026
- Oct 5, 2026Planned saleMANUELA VALENTE (officer) filed notice to sell about $34,217 around Oct 5, 2026
- Oct 5, 2026Planned saleGEORGE CARDOZA (officer) filed notice to sell about $12,847 around Oct 5, 2026
- Sep 21, 2026Insider saleCFO George Cardoza sold $6,447 under a 10b5-1 plan
- Sep 21, 2026Insider saleCEO Ross Muken sold $3,515 under a 10b5-1 plan
- Sep 21, 2026Planned saleGEORGE CARDOZA (officer) filed notice to sell about $6,339 around Sep 21, 2026
- Sep 21, 2026Planned saleROSS J MUKEN (director, officer) filed notice to sell about $3,456 around Sep 21, 2026
- Sep 14, 2026Insider saleChief Medical Officer Philippe Menu sold $39,417
- Sep 14, 2026Insider saleChief Scientific Officer Zhenyu Xu sold $31,538 under a 10b5-1 plan
- Sep 11, 2026Insider saleGeneral Counsel Van Well Daan sold $47,089 under a 10b5-1 plan
- Sep 11, 2026Planned saleDAAN GUIDO MARIA VAN WELL (officer) filed notice to sell about $46,938 around Sep 11, 2026
- Sep 10, 2026Insider saleExecutive Chair Jurgi Camblong sold $65,120 under a 10b5-1 plan
- Sep 8, 2026Insider saleDirector Kathy L. Hibbs sold $50,818 under a 10b5-1 plan
- Aug 27, 2026Insider saleChief Scientific Officer Zhenyu Xu sold $89,096 under a 10b5-1 plan
- Aug 27, 2026Planned saleZHENYU XU (officer) filed notice to sell about $119,420 around Aug 27, 2026
- Aug 25, 2026Insider saleDirector Kathy L. Hibbs sold $54,233 under a 10b5-1 plan
- Aug 25, 2026Insider saleChief Medical Officer Philippe Menu sold $43,397 under a 10b5-1 plan
- Aug 25, 2026Planned saleKATHY L HIBBS (director) filed notice to sell about $158,438 around Aug 25, 2026
- Aug 24, 2026Insider saleCTO Abhimanyu Verma sold $44,000 under a 10b5-1 plan
- Aug 21, 2026Insider saleChief Scientific Officer Zhenyu Xu sold $45,447 under a 10b5-1 plan
- Aug 20, 2026Insider saleChief Scientific Officer Zhenyu Xu sold $38,609 under a 10b5-1 plan
- Aug 20, 2026Planned saleZHENYU XU (officer) filed notice to sell about $49,680 around Aug 20, 2026
- Aug 19, 2026Insider saleCTO Abhimanyu Verma sold $41,000 under a 10b5-1 plan
- Aug 19, 2026Insider saleChief People Officer Manuela Valente sold $79,439 under a 10b5-1 plan
Showing the latest 40 of 46 events.
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 14, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 14 | Jurgi CamblongExecutive Chair | ▼ SELL10b5-1 | $62K |
| Oct 14 | Philippe MenuChief Medical Officer | ▼ SELL10b5-1 | $36K |
| Oct 14 | Zhenyu XuChief Scientific Officer | ▼ SELL10b5-1 | $29K |
| Oct 7 | Jurgi CamblongExecutive Chair | ▼ SELL10b5-1 | $327K |
| Oct 7 | Ross MukenCEO | ▼ SELL10b5-1 | $80K |
| Oct 7 | Philippe MenuChief Medical Officer | ▼ SELL10b5-1 | $60K |
| Oct 7 | Zhenyu XuChief Scientific Officer | ▼ SELL10b5-1 | $60K |
| Oct 7 | Van Well DaanGeneral Counsel | ▼ SELL10b5-1 | $50K |
| Oct 7 | Abhimanyu VermaCTO | ▼ SELL10b5-1 | $43K |
| Oct 7 | Manuela ValenteChief People Officer | ▼ SELL10b5-1 | $34K |
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Jurgi Camblong | Executive Chair | 0 | $0 | 3 | $453K |
| Philippe Menu | Chief Medical Officer | 0 | $0 | 5 | $217K |
| Zhenyu Xu | Chief Scientific Officer | 0 | $0 | 8 | $403K |
| Ross Muken | CEO | 0 | $0 | 2 | $83K |
| Van Well Daan | General Counsel | 0 | $0 | 2 | $97K |
| Abhimanyu Verma | CTO | 0 | $0 | 3 | $128K |
| Manuela Valente | Chief People Officer | 0 | $0 | 2 | $114K |
| George Cardoza | CFO | 0 | $0 | 2 | $19K |
A 1 of 30 insider trades reported after the deadline. How it is graded
Tracked funds that report SOPH
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Akre Capital Management | 3,719,140 | $21.5M | No change |
| Renaissance Technologies | 113,300 | $654K | ▲ +89.5% |
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →